Across TCGA pan-cancer cohorts, RAET1G Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAET1G data layer compared with 26 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher RAET1G Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAET1G expression acts as an unfavorable survival marker.

READ, BLCA, and PRAD are the cancer types where RAET1G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.198	0.829	.001	26	view →
BLCA	OS	Median	All	0.269	0.610	.044	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RAET1G tumor-vs-normal RNA expression · all RAET1G data types